# A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

> **NCT00724919** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 256 (actual)

## Conditions studied

- Infection

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00724919
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2008-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724919, "A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00724919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*